ALPMY should take 4%ALPMY could grow and cross or at least touch the 20 days average around 13.25$
Would be a 4% growth
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.196 EUR
104.37 M EUR
9.82 B EUR
1.71 B
About ASTELLAS PHARMA
Sector
Industry
CEO
Naoki Okamura
Website
Headquarters
Tokyo
Founded
1923
ISIN
JP3942400007
FIGI
BBG000BL2FR5
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ASTELLAS PHARMA INC. stocks are traded under the ticker YPH.
We've gathered analysts' opinions on ASTELLAS PHARMA INC. future price: according to them, YPH price has a max estimate of 14.80 EUR and a min estimate of 8.63 EUR. Watch YPH chart and read a more detailed ASTELLAS PHARMA INC. stock forecast: see what analysts think of ASTELLAS PHARMA INC. and suggest that you do with its stocks.
Yes, you can track ASTELLAS PHARMA INC. financials in yearly and quarterly reports right on TradingView.
ASTELLAS PHARMA INC. is going to release the next earnings report on Apr 25, 2025. Keep track of upcoming events with our Earnings Calendar.
YPH earnings for the last quarter are −0.34 EUR per share, whereas the estimation was 0.15 EUR resulting in a −322.43% surprise. The estimated earnings for the next quarter are 0.13 EUR per share. See more details about ASTELLAS PHARMA INC. earnings.
ASTELLAS PHARMA INC. revenue for the last quarter amounts to 3.18 B EUR, despite the estimated figure of 2.75 B EUR. In the next quarter, revenue is expected to reach 2.73 B EUR.
YPH net income for the last quarter is −599.99 M EUR, while the quarter before that showed 224.37 M EUR of net income which accounts for −367.41% change. Track more ASTELLAS PHARMA INC. financial stats to get the full picture.
ASTELLAS PHARMA INC. dividend yield was 4.26% in 2023, and payout ratio reached 736.46%. The year before the numbers were 3.19% and 110.62% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 20, 2025, the company has 14.75 K employees. See our rating of the largest employees — is ASTELLAS PHARMA INC. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ASTELLAS PHARMA INC. EBITDA is 2.65 B EUR, and current EBITDA margin is 20.95%. See more stats in ASTELLAS PHARMA INC. financial statements.
Like other stocks, YPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASTELLAS PHARMA INC. stock right from TradingView charts — choose your broker and connect to your account.